Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32

BACKGROUND: BM32 is a grass pollen allergy vaccine based on recombinant fusion proteins consisting of nonallergenic peptides from the IgE-binding sites of the 4 major grass pollen allergens and the hepatitis B preS protein. OBJECTIVE: We sought to study the safety and clinical efficacy of immunother...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Allergy Clin Immunol
Prif Awduron: Niederberger, Verena, Neubauer, Angela, Gevaert, Philippe, Zidarn, Mihaela, Worm, Margitta, Aberer, Werner, Malling, Hans Jørgen, Pfaar, Oliver, Klimek, Ludger, Pfützner, Wolfgang, Ring, Johannes, Darsow, Ulf, Novak, Natalija, van Wijk, Roy Gerth, Eckl-Dorna, Julia, Focke-Tejkl, Margarete, Weber, Milena, Müller, Hans-Helge, Klinger, Joachim, Stolz, Frank, Breit, Nora, Henning, Rainer, Valenta, Rudolf
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6392176/
https://ncbi.nlm.nih.gov/pubmed/29361332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2017.09.052
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg